BCDAWBioCardia, Inc.
—Mkt Cap: —P/E: —788d ago
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)468.00K $
Gross Profit-6.12M $
Net Income (TTM)-8.23M $
Revenue/Share0.3130 USD
Last Price—
Fiscal Year End—
MR Quarter—
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)-3.20
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin0.00%
Oper. Margin-4136.36%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-919.33%
ROA-241.08%
Growth
Revenue Growth-14.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.44M $
CapEx (TTM)7.00K $
FCF Margin-1131.54%
FCF Yield—
Net Debt279.00K $
Net Debt/EBITDA-0.03
Balance Sheet
Debt/Equity0.59
Current Ratio0.31
Quick Ratio0.25
Book Value/Sh-1.2720 USD
Cash/Share0.5210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float1.21M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.36
S&P 52W Chg16.25%
Avg Vol (30d)—
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—